Sanofi to cut U.S. insulin prices by up to 78%, capping cost at $35

Sanofi is cutting the list price of Lantus, its most widely prescribed insulin in the US, by 78% and establishing a $35 monthly cap for those with private insurance, the company announced Thursday. The change is effective January 1.

Then, Novo Nordisk said Tuesday that it will slash the list prices of several of its popular pre-filled insulin pens and vials by up to 75%. However, the company did not announce an expansion of its programs that cut patients' out-of-pocket costs, which has been a focus of President Joe Biden and congressional Democrats. It runs several programs to lower costs for people with diabetes.

Last year, congressional Democrats passed the Inflation Reduction Act, which reduces Medicare beneficiaries' out-of-pocket cost for insulin to $35 per month per prescription starting this year. Republicans blocked a measure to extend that price cap to those covered by private insurance. Demand for insulin has grown significantly as diabetes has become the fastest-growing chronic disease in the world, a 2022 study found.

Because California came out with its own insulin ThanksGav

Business Business Latest News, Business Business Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Sanofi to cut U.S. insulin prices by up to 78%, capping cost at $35Sanofi is cutting the list price of Lantus, its most widely prescribed insulin in the US, by 78%, the company announced. Thanks Dark Brandon
Source: ABC7NY - 🏆 592. / 51 Read more »

Sanofi to cut U.S. insulin prices by up to 78%, capping cost at $35Sanofi is cutting the list price of its insulin in the U.S. by 78%, establishing a $35 monthly cap for the privately insured.
Source: ABC7Chicago - 🏆 284. / 63 Read more »